Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Aul

Showing results (151-160 of 177) with videos related to

Pageof 18
Sort By:
Annals of Hematology|November 7, 1999
Factors influencing G-CSF-mediated mobilization of hematopoietic progenitor cells during steady-state hematopoiesis in patients with malignant lymphoma and multiple myelomaG Kobbe, D Söhngen, U Bauser, et al.
Leukemia|February 3, 2007
Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classificationA Matsuda, U Germing, I Jinnai, et al.
Journal of Cancer Research and Clinical Oncology|June 11, 1999
Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromesW Verbeek, B Wörmann, P Koch, et al.
European Journal of Haematology|June 20, 2002
Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cellsM Aivado, A Rong, M Stadler, et al.
Leukemia|January 22, 1998
Idarubicin, melphalan and cyclophosphamide: an intensified high-dose regimen for the treatment of myeloma patientsA Heyll, D Söhngen, G Kobbe, et al.
Blood|March 15, 1997
International scoring system for evaluating prognosis in myelodysplastic syndromesP Greenberg, C Cox, M M LeBeau, et al.
Leukemia|January 9, 2004
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromesM Stadler, U Germing, K-O Kliche, et al.
Leukemia|August 30, 2002
Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factorsM Oosterveld, P Muus, S Suciu, et al.
Blood|June 11, 1999
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative GroupT Büchner, W Hiddemann, B Wörmann, et al.
Bone Marrow Transplantation|March 7, 1998
Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationV Runde, T de Witte, R Arnold, et al.
Pageof 18

Showing results (151-160 of 177) with videos related to

Sort By:
Pageof 18
Annals of Hematology|November 7, 1999
Factors influencing G-CSF-mediated mobilization of hematopoietic progenitor cells during steady-state hematopoiesis in patients with malignant lymphoma and multiple myelomaG Kobbe, D Söhngen, U Bauser, et al.
Leukemia|February 3, 2007
Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classificationA Matsuda, U Germing, I Jinnai, et al.
Journal of Cancer Research and Clinical Oncology|June 11, 1999
Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromesW Verbeek, B Wörmann, P Koch, et al.
European Journal of Haematology|June 20, 2002
Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cellsM Aivado, A Rong, M Stadler, et al.
Leukemia|January 22, 1998
Idarubicin, melphalan and cyclophosphamide: an intensified high-dose regimen for the treatment of myeloma patientsA Heyll, D Söhngen, G Kobbe, et al.
Blood|March 15, 1997
International scoring system for evaluating prognosis in myelodysplastic syndromesP Greenberg, C Cox, M M LeBeau, et al.
Leukemia|January 9, 2004
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromesM Stadler, U Germing, K-O Kliche, et al.
Leukemia|August 30, 2002
Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factorsM Oosterveld, P Muus, S Suciu, et al.
Blood|June 11, 1999
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative GroupT Büchner, W Hiddemann, B Wörmann, et al.
Bone Marrow Transplantation|March 7, 1998
Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationV Runde, T de Witte, R Arnold, et al.
Pageof 18